{"product_id":"global-lyme-disease-diagnostic-market-size-study-forecast-by-emerging-diagnostic-technology-serological-test-urine-antigen-tests-lymphocytic-transformation-test-immunofluorescent-staining-nucleic-acid-test-by-end-user-hospitals-public-private","title":"Global Lyme Disease Diagnostic Market Size study \u0026 Forecast, by Emerging Diagnostic Technology (Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nucleic acid Test), by End User (Hospitals, Public\/Private","description":"\u003cp\u003eGlobal Lyme Disease Diagnostic Market Size study \u0026amp; Forecast, by Emerging Diagnostic Technology (Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nucleic acid Test), by End User (Hospitals, Public\/Private Laboratories, Physicians Office) and Regional Analysis, 2022-2029\u003cbr\u003e\nGlobal Lyme Disease Diagnostic Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Lyme disease is a bacterial infection caused by Borrelia burgdorferi. It is transmitted to humans through the bite of an infected black-legged tick. The symptoms of Lyme disease can be similar to other illnesses such as flu-like symptoms, fever, and fatigue, making it difficult to diagnose. In the early stages of Lyme disease, a characteristic rash called erythema migraines may develop. However, not all patients develop this rash, and in later stages, Lyme disease can affect the nervous system, heart, and joints. The key factor driving the market growth is growing prevalence of Lyme disease, favorable government initiative towards healthcare facilities, and emergence of new Lyme diagnostic tests that anticipated to create the lucrative demand for the market during forecast period.\u003c\/p\u003e\n\n\u003cp\u003eMoreover, the rise in prevalence of Lyme disease is anticipated to create the lucrative demand for the market. For instance, according to the Centres for Disease Control and Prevention, there were 47,743 tick-borne disease cases reported in 2021, which led the development of Lyme disease diagnostic tests. For another example, the United States Fair Health Organization announced in 2022 that Lyme disease had increased significantly over the previous 15 years in the United States and had consequently become a condition of rising national concern. According to the same source, private insurance claim lines for Lyme disease diagnosis increased by 357 percent in rural areas and by 65 percent in urban areas in 2021 compared to the previous ten years. Additionally, the rising research and development in Lyme disease diagnostic is anticipated to create the lucrative opportunity for the market during forecast period. However, the lack of awareness regarding the disease stifles market growth throughout the forecast period of 2022-2029.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Lyme Disease Diagnostic Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, and cohesive government initiatives for diagnosing and treatment of various diseases. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as rising Lyme disease cases and growing public and private investment in healthcare sector for better diagnostics system would create lucrative growth prospects for the Lyme Disease Diagnostic market across Asia Pacific region.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nT2 Biosystems\u003cbr\u003e\nCanon Life Sciences\u003cbr\u003e\nBio Rad Laboratories\u003cbr\u003e\nAlere Inc.\u003cbr\u003e\nRoche Diagnostics International Ltd.\u003cbr\u003e\nGraphene Frontiers\u003cbr\u003e\nCovance Inc.\u003cbr\u003e\nImmunetics Inc.\u003cbr\u003e\nGlaxoSmithKline\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\nIn July, 2022, the United States Food and Drug Administration (USFDA) approved T2Biosystems and T2Lyme Panel. The T2Lyme Panel is intended to enable more precise early Lyme disease diagnosis, which may help to enhance care and improve patient outcomes. The T2Lyme Panel uses a patient's blood to identify bacteria that cause Lyme disease.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Lyme Disease Diagnostic Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Emerging Diagnostic Technology, End User, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.\u003c\/p\u003e\n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Emerging Diagnostic Technology:\u003cbr\u003e\nSerological Test\u003cbr\u003e\nUrine Antigen Tests\u003cbr\u003e\nLymphocytic Transformation Test\u003cbr\u003e\nImmunofluorescent Staining\u003cbr\u003e\nNucleic acid Test\u003cbr\u003e\nBy End User:\u003cbr\u003e\nHospitals\u003cbr\u003e\nPublic\/Private Laboratories\u003cbr\u003e\nPhysicians Office\u003cbr\u003e\nBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRoLA\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eAbbott Laboratories\u003cbr\u003e\nT2 Biosystems\u003cbr\u003e\nCanon Life Sciences\u003cbr\u003e\nBio Rad Laboratories\u003cbr\u003e\nAlere Inc.\u003cbr\u003e\nRoche Diagnostics International Ltd.\u003cbr\u003e\nGraphene Frontiers\u003cbr\u003e\nCovance Inc.\u003cbr\u003e\nImmunetics Inc.\u003cbr\u003e\nGlaxoSmithKline\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 200 Pages \/ MCW16236730","offer_id":47652266541362,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-lyme-disease-diagnostic-market-size-study-forecast-by-emerging-diagnostic-technology-serological-test-urine-antigen-tests-lymphocytic-transformation-test-immunofluorescent-staining-nucleic-acid-test-by-end-user-hospitals-public-private","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}